For research use only
| Cat No. | ABC-TC0886 |
| Product Type | Human Ovarian Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Product Code | OV SAHO, ovsaho |
OVSAHO human ovarian carcinoma cells with TP53 mutation, epithelial morphology, tumorigenic, HPV/EBV-negative, used for ovarian cancer and p53 pathway.
OVSAHO is a permanent epithelial ovarian carcinoma cell line derived from a peritoneal metastasis of a primary high-grade serous adenocarcinoma of the ovary (FIGO stage III) in a 56-year-old Japanese female patient. OVSAHO is widely used in ovarian cancer research as a representative model of high-grade serous ovarian carcinoma (HGSOC). The cells grow adherently in monolayer culture and exhibit epithelial morphology with a moderately polygonal shape. The cells grow adherently in monolayer culture, exhibiting polygonal epithelial morphology, and express a broad panel of cytokeratins, including CK6, CK7, CK8, CK14, CK15/16, CK18, and CK19, consistent with Müllerian epithelial origin. Molecular profiling has identified a TP53 nonsense mutation (c. 1024C>T; p. Arg342Ter), a hallmark of HGSOC, while the BRCA1 gene remains wild-type. OVSAHO cells are tumorigenic in both immunodeficient and immunocompetent murine models when introduced via subcutaneous, intraperitoneal, or orthotopic injection routes; however, they do not demonstrate spontaneous metastatic potential in vivo. OVSAHO provides a robust preclinical platform for investigating HGSOC pathogenesis and p53-related molecular pathways.
| Product Code | OV SAHO, ovsaho |
| Species | Human |
| Cat.No | ABC-TC0886 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Ovarian Cancer Cell Lines |
The OVSAHO cell line is widely used in ovarian cancer research. As one of the frequently employed tumor models, it important for in vitro screening of experimental anticancer agents. Researchers can rely on OVSAHO to explore specific histologic subtypes and the response to various agents. Additionally, OVSAHO’s utility extends to xenograft models, where supports xenograft-based preclinical drug testing, contributing to the advancement of ovarian cancer treatment strategies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
